Key Highlights
● A New Drug Application for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) has been submitted to the FDA by AstraZeneca.
● The submission is based on the global SAFFRON Phase III trial, enrolling 338 patients at 230 centers in 29 countries.
● The release says SAFFRON showed statistically significant improvement in progression-free and overall survival versus chemotherapy, with a consistent safety profile.
● The combination is already approved in China for MET amplification, based on SACHI, and has temporary authorization in Switzerland.
HUTCHMED (China) Limited (NASDAQ:HCM) furnished a Form 6-K on September 29, 2026, containing a press release announcing that a New Drug Application has been submitted to the U.S. Food and Drug Administration for ORPATHYS (savolitinib) in combination with TAGRISSO (osimertinib). The press release states that AstraZeneca submitted the application and that HUTCHMED is announcing it. The submission is based on results from the global SAFFRON Phase III trial.
The Proposed Indication
The release says the application covers patients with locally advanced or metastatic non-small cell lung cancer, or NSCLC, that has an EGFR mutation and whose tumors show MET overexpression or amplification after disease progression on treatment with an EGFR tyrosine kinase inhibitor. It describes savolitinib as an oral, selective MET tyrosine kinase inhibitor and osimertinib as a third-generation, irreversible EGFR tyrosine kinase inhibitor that is approved in more than 120 countries. TAGRISSO is AstraZeneca's Brand name for osimertinib.
What SAFFRON Studied
SAFFRON is described as a randomized, open-label Phase III trial that enrolled 338 patients at 230 centers in 29 countries. It compared savolitinib at 300 mg twice daily plus osimertinib at 80 mg once daily against doublet platinum-based chemotherapy. The primary endpoint was progression-free survival, and overall survival was a key secondary endpoint.
On results, the release states that the trial demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival and overall survival, with a consistent safety profile. The release does not provide hazard ratios, median survival times or other numerical results, so those figures are not available from this filing.
The release notes that the combination is already approved in China for patients with MET amplification, based on the SACHI Phase III trial, and has been granted temporary authorization in Switzerland. It does not describe any FDA designation, and it does not mention Fast Track or breakthrough status.
Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer, is quoted in the release as saying that the filing is "an important step toward potentially bringing" the combination to patients in the U.S., after its approval in China. The release identifies HUTCHMED as listed on Nasdaq and AIM under the symbol HCM and on the Hong Kong exchange under the code 13.
What the Filing Does and Does Not Say
A New Drug Application is the formal request that a drug sponsor submits to the FDA seeking permission to market a medicine in the United States. Submission starts the agency's review process, but it is not an approval, and the release does not report that the FDA has accepted the application for filing. The release does not state a decision date or review timeline.
A Form 6-K is the form a foreign private issuer uses to furnish information it has made public elsewhere, and this one is a short cover document that furnishes the press release as Exhibit 99.1.
FDA Acceptance Step for ORPATHYS Plus TAGRISSO
The next milestone would be the FDA's decision on whether to accept the application for review, which the release does not date.
Other points to watch are the presentation of the detailed SAFFRON results, which the release does not schedule, and any further news on the approval in China or the temporary authorization in Switzerland.


_11_17_2026_13_39_08_971706.jpg)



Please wait processing your request...